leuprorelin cross pharma 5 mg implantat
cross pharma ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin 2care4 5 mg implantat
2care4 aps - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin pharmachim 5 mg implantat
pharmachim ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprostin 5 mg implantat
medartuum ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
firmagon
ferring pharmaceuticals a/s - degarelix - prostatiska neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
letrozol 2care4 2,5 mg filmdragerad tablett
2care4 aps - letrozol - filmdragerad tablett - 2,5 mg - letrozol 2,5 mg aktiv substans; laktosmonohydrat hjälpämne
letrozol orion 2,5 mg filmdragerad tablett
orion corporation - letrozol - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; tartrazin aluminiumlack hjälpämne; letrozol 2,5 mg aktiv substans
leuprorelin 2care4 5 mg implantat
2care4 aps - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans
leuprorelin medartuum 5 mg implantat
medartuum ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans
leuprorelin orifarm 5 mg implantat
orifarm ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans